Rapid Transdermal Delivery of Opioid Pain Medications

Information

  • Research Project
  • 6550710
  • ApplicationId
    6550710
  • Core Project Number
    R43GM066609
  • Full Project Number
    1R43GM066609-01
  • Serial Number
    66609
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/15/2002 - 22 years ago
  • Project End Date
    1/14/2003 - 21 years ago
  • Program Officer Name
    CHEUNG, GEOFFREY P.
  • Budget Start Date
    7/15/2002 - 22 years ago
  • Budget End Date
    1/14/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    7/8/2002 - 22 years ago
Organizations

Rapid Transdermal Delivery of Opioid Pain Medications

DESCRIPTION (provided by applicant): The American Medical Association reports that undertreatment of pain is a major problem for cancer patients as well as for other disease conditions. Approximately 50-75% of cancer patients have pain that is undertreated, and 25% die in severe unrelieved pain. Noninvasive pain medication delivery systems are ideally suited to improve the quality of life for those who experience chronic pain. Currently available noninvasive systems are slow, variable, or require frequent dosing. The goal of this project is to demonstrate the capability of a novel thermal microporation method to enable rapid infusion of pain medication through the skin. The microporation method is a noninvasive, painless, needless, patch-based system which creates an array of microscopic openings in the stratum corneum that increases the drug flux significantly compared to drugs delivered through intact skin. Four top opioid candidates for microporation delivery will be evaluated with an in vitro drug delivery model system that involves studying freshly harvested hairless mouse skin to determine optimal formulation and microporation delivery parameters. The opioid candidates to be tested in vitro with the thermal microporation method include morphine, hydromorphone, fentanyl, and alfentanil. A small pilot clinical study will also be performed to determine the feasibility of delivering fentanyl with a commercially available transdermal patch in conjunction with the microporation system.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    105650
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:105650\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ALTEA THERAPEUTICS CORPORATION
  • Organization Department
  • Organization DUNS
    134092803
  • Organization City
    Atlanta
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    30313
  • Organization District
    UNITED STATES